* NANOBIOTIX *
2003 - IDF
Paris
www.nanobiotix.com Design, Drugs
Key words: Nanoparticles, Cancer, NanoXray, Nbtxr3
Mission: to develop new cancer treatments based on proprietary NanoXray platform, as an injection of patented X-ray activated nanoparticles
Clients: Hospitals
mail@nanobiotix.com
Age: 9 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Levy (Laurent) [co-founder, born 1971, Ph.D. physical chemistry, ex-Altran]
Sc.Dir.-CSO:
Oper.Dir.-COO: Boussaha (Kader) [co-founder, born 1973, Eng. ENI, ex-Altran]
Med.Dir.: Borghi (Elsa) [M.D., ex-Sanofi-Aventis]
Fin.Dir.-CFO:
BusDev: Mühlenweg (Bernd) [Ph.D. chemistry, Munich, ex-Wilex]
Financers (Hist.): Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management | Turnover (M€) : 1.58 (2009), 0.92 (2008), 0.5 (2007)
Total funding (M€) : 16.3
Last funding (M€) : 8.3
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .06 | 3rd round-financing : 8.3 M€, led by CIC Vizille Capital Innovation with Masseran Gestion, and existing shareholders, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes | RFINC | [7 years] |
| 2009 .01 | Partnering research agreement with SonoDrugs consortium (Philips, Lipoid AG, and 13 universities within a 16 M€ budget) to develop new nanoparticulate drug carriers | R&D | [5 years] |
| 2008 .09 | Patent : granted on nanoXray anticancer platform (Europe) | LEGAL | [5 years] |
| 2006 .11 | 2nd round-financing : 7.0 M€, by Matignon Technologies, OTC Asset Management, and previous shareholders | RFINB | [3 years] |
| 2005 .03 | Company move from Labège (near Toulouse) to Paris | ORGL | [2 years] |
| 2004 .00 | 1st round-financing : 1.0 M€, by Buffalo University (USA) and founders | RFINA | [0 year] |
| 2003 .03 | Company founded by Laurent Levy (born 1971), Kader Boussaha , and 4 others | ORGF | [0 year] | Actualisation / Updating: 9-May-2011 |
|
